Drug
Elifibranor clinical trials
Also written GFT505, Elafibranor and IPN60190.
- studies test it
- 23
- open now
- 2
- in phase 3
- 6
- first study started
- 2009
Keep track of what changes. Save the elifibranor studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Other names
Studies by the year they started
23 studies that test it; most in 2019 (5)
| Year | Studies |
|---|---|
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 5 |
| 2020 | 1 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 9
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 23 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses elifibranor is read from its arms, and is right about nine times in ten.
Testing it · 23
- A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary CholangitisRecruitingPhase 3IpsenNCT06016842Written as Elafibranor
- A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing CholangitisRecruitingPhase 3IpsenNCT07387549Written as Elafibranor
- A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.Active, not recruitingPhase 2IpsenNCT05627362Written as Elafibranor 80 mg
- A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)Active, not recruitingPhase 3IpsenNCT06730061Written as Elafibranor
- Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)Active, not recruitingPhase 3IpsenNCT04526665Written as Elafibranor 80mg
- A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.CompletedPhase 3IpsenNCT06383403Written as Elafibranor
- Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy ParticipantsCompletedPhase 1IpsenNCT05543369Written as Elafibranor
- A Study to Evaluate the Effect of Food on the Level of Circulating Elafibranor in Healthy Participants After Intake of a Single TabletCompletedPhase 1IpsenNCT05564208Written as elafibranor
- Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)CompletedPhase 2GenfitNCT01694849Written as GFT505 80mg
- Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)TerminatedPhase 3GenfitNCT02704403Written as Elafibranor
- Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)TerminatedPhase 2GenfitNCT03883607Written as Elafibranor 80mg
- Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)TerminatedPhase 2GenfitNCT03953456Written as elafibranor 120mg
- Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and IndomethacinCompletedPhase 1GenfitNCT03985969Written as elafibranor
- Elafibranor Pharmacokinetic Parameters in Renal Impaired PatientsCompletedPhase 1GenfitNCT03844555Written as Elafibranor
- Elafibranor Pharmacokinetic Parameters in Elderly Healthy VolunteersCompletedPhase 1GenfitNCT04171752Written as elafibranor
- Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic AcidCompletedPhase 2GenfitNCT03124108Written as Elafibranor 80 mg
- Elafibranor Pharmacokinetic Parameters in Hepatic Impaired PatientsCompletedPhase 1GenfitNCT03765671Written as Elafibranor
- Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy VolunteersCompletedPhase 1GenfitNCT02091310Written as GFT505
- Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505CompletedPhase 1GenfitNCT01474161Written as GFT505 120mg - old formulation
- Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal ObesityCompletedPhase 2GenfitNCT01271777Written as GFT505 80mg
Codes
What other systems call elifibranor · ClinicalTrials.gg INT006416
- MeSH (NLM) C585906elifibranorConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 2J3H5C81A5ELAFIBRANORConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C585906 | elifibranor | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 2J3H5C81A5 | ELAFIBRANOR | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.